Anti-NCoA-3 Antibody

NCoA-3 (Nuclear Receptor Coactivator 3), also referenced as SRC-3 or AIB1, belongs to the p160 family of steroid receptor coactivators that bridge ligand-bound nuclear receptors with the basal transcriptional machinery. It amplifies transactivation by estrogen, androgen, progesterone, and glucocorticoid receptors and has been studied extensively in hormone-driven cancers, particularly breast and ovarian tumors where the gene is frequently amplified on chromosome 20q13. This unconjugated Rabbit polyclonal reagent from Antibodies.com is raised against the human protein and has been validated for Western blot and ELISA applications, with reactivity confirmed against human, mouse, and rat samples. The 100 µl volume supports multiple immunoblot membranes and is well suited to time-course or dose-response experiments in cell lysates and tissue homogenates. Typical research uses include profiling coactivator expression across tumor versus matched normal tissue, examining post-translational modifications such as phosphorylation and acetylation that regulate NCoA-3 stability and activity, and probing chromatin remodeling complex assembly at hormone response elements. Investigators working on SRC-1 and SRC-2 cross-comparisons, nuclear receptor signaling cascades, or siRNA and CRISPR knockout validation studies rely on polyclonal recognition of multiple epitopes to track both endogenous and overexpressed protein levels under varying experimental conditions.